Cabozantinib for non-clear renal cell cancer histologies – pro
Cabozantinib is a small-molecule tyrosine kinase inhibitor (TKI). It exerts inhibition of MET, vascular endothelial growth factor receptor type 2, AXL, and many other receptor tyrosine kinases that are also implicated in tumor pathobiology, including RET, KIT, and FLT3. It is approved for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. However, responses have also been reported in non-renal cell histologies, to the extent that NCCN recommends it in such cases. Non-clear cell histologies represent only around 10% of kidney cancers. Mutations in the HGF and MET genes are associated with bilateral type I papillary renal carcinoma (pRCC) in hereditary pRCC syndrome, for example. As such, it is ana ctive agent on non-clear histologies as well.
Malouf GG, Flippot R, Khayat DTherapeutic Strategies for Patients With Metastatic Renal Cell Carcinoma in Whom First-Line Vascular Endothelial Growth Factor Receptor-Directed Therapies Fail.J Oncol Pract. 2016 May;12(5):412-20.
Steven S Yu, David I Quinn, and Tanya B Dorf, Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection
Onco Targets Ther. 2016; 9: 5825–5837.
.
NCCN KID-4, 2017